CDKN2A and cancer: They propose p16 as a biomarker for identification of truly basal-like cancers and raise the possibility that triple-negative breast cancer with basal cytokeratin, and p16 co-expression may adequately identify these tumours and serve as a potential diagnostic/prognostic biomarker.